We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
- Authors
Gianolio, Diego A; Rouleau, Cecile; Bauta, William E; Lovett, Dennis; Cantrell, William R, Jr; Recio, Antonio, 3rd; Wolstenholme-Hogg, Paul; Busch, Michelle; Pan, Peng; Stefano, James E; Kramer, Hildegard M; Goebel, James; Krumbholz, Roy D; Roth, Stephanie; Schmid, Steven M; Teicher, Beverly A
- Abstract
Targeting tubulin binders to cancer cells using antibody-drug conjugates (ADCs) has great potential to become an effective cancer treatment with low normal tissue toxicity. The nature of the linker used to tether the tubulin binder to the antibody and the conjugation sites on the antibody and the small molecule are important factors in the ADC stability and effectiveness.
- Publication
Cancer chemotherapy and pharmacology, 2012, Vol 70, Issue 3, p439
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-012-1925-8